Biliary Tract Neoplasms Clinical Trial
Official title:
The Role of ctDNA and PBMC as Biomarkers in Diagnostic, Efficacy Monitoring and Prognostic Evaluation of Biliary Tract Cancer
Our study aims to evaluate the role of ct-DNA and PBMC as biomarkers in the treatment of biliary tract cancer.
Biliary cancer ranked fifth in all gastrointestinal malignant cancer. Epidemiological surveys
showed a significant increasing trend in recent years. How can make an early diagnosis of
bile duct cancer as well as prognostic evaluation and efficacy monitoring, has become the
hotspot. "liquid biopsy", which is meant to detect cancers by sequencing the DNA in a few
drops of a person's blood. It may detect cancers early, even before symptoms arise, when
there is just a few cells in the blood circulation.
cf-DNA in cancer patients often bears similar genetic and epigenetic features to the related
tumor DNA. There is evidence that some of the cf-DNA originates from tumoral tissue. This,
and the fact that cf-DNA can easily be isolated from the circulation and other body fluids of
patients, makes it a promising candidate as a non-invasive biomarker of cancer. And we call
the cf-DNA of tumor as ct-DNA.
Peripheral blood mononuclear cells (PBMC) is any peripheral blood cell having a round
nucleus. These cells can be extracted from whole blood using ficoll, a hydrophilic
polysaccharide. PBMC contains genetic material of tumor and may be applied as a biomarker.
This study aims to evaluate the role of ct-DNA and PBMC as biomarkers in the treatment of
biliary tract cancer.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT01950572 -
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
|
||
| Completed |
NCT03101566 -
Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer
|
Phase 2 | |
| Recruiting |
NCT05237193 -
A Prospective Study of UCAD for Diagnosing Benign or Malignant Biliary Obstruction and Follow-up
|
||
| Not yet recruiting |
NCT06037655 -
Chemotherapy Combined With Adebrelimab and Mecapegfilgrastim in Neoadjuvant Treatment of Potentially Resectable BTC
|
Phase 2 | |
| Recruiting |
NCT04584008 -
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
|
N/A | |
| Completed |
NCT00196105 -
Malignant Obstruction ZILVER Against Routine Therapy (MOZART I)
|
N/A | |
| Completed |
NCT02558959 -
Second-line Irinotecan and Capecitabine Versus Irinotecan for Gemcitabine and Cisplatin Refractory Biliary Tract Cancer
|
Phase 2 | |
| Completed |
NCT02829918 -
Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
|
Phase 2 | |
| Completed |
NCT02784353 -
Clinical Outcomes of Preoperative and Postoperative Rehabilitation in the Patients With HBP Malignancy
|
N/A | |
| Recruiting |
NCT05429203 -
Comparison of Duodenoscope With Single-use Distal Cover and the Conventional Reusable Duodenoscope
|
N/A | |
| Recruiting |
NCT02255669 -
Fully Covered SEMS Versus Partially Covered SEMS With Anti-migration System for Malignant Distal Biliary Obstruction
|
N/A | |
| Completed |
NCT01731821 -
Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy After Pancreaticoduodenectomy
|
Phase 3 | |
| Completed |
NCT00422409 -
Endoscopic Stenting of Gastrointestinal Cancer
|
N/A | |
| Terminated |
NCT02900248 -
CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice
|
||
| Recruiting |
NCT03063554 -
EUS BD vs ERCP TP for Pancreatic Cancer
|
N/A | |
| Terminated |
NCT02615210 -
Mid-Atlantic Research Group Single-Operator Cholangioscopic Assessment of Biliary Strictures
|
N/A | |
| Completed |
NCT04595058 -
LAMS Choledochoduodenostomies: With or Without Coaxial Plastic Stent
|
N/A | |
| Recruiting |
NCT04856761 -
A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection
|
||
| Recruiting |
NCT03427242 -
Apatinib for Advanced Biliary Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05615818 -
Personalized Medicine for Advanced Biliary Cancer Patients
|
Phase 3 |